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Background and purpose of the study: The objective of the study was to develop and characterize Diclofenac
Diethylamine (DDEA) transdermal patch using Silicone and acrylic adhesives combination.
Methods: Modified solvent evaporation method was employed for casting of film over Fluoropolymer coated
polyester release liner. Initial studies included solubilization of drug in the polymers using solubilizers. The
formulations with combination of adhesives were attempted to combine the desirable features of both the
adhesives. The effect of the permeation enhancers on the drug permeation were studied using pig ear skin. All the
optimized patches were subjected to adhesion, dissolution and stability studies. A 7-day skin irritancy test on albino
rabbits and an in vivo anti-inflammatory study on wistar rats by carrageenan induced paw edema method were
also performed.
Results: The results indicated the high percent drug permeation (% CDP-23.582) and low solubility nature (1%) of
Silicone adhesive and high solubility (20%) and low% CDP (10.72%) of acrylic adhesive. The combination of
adhesives showed desirable characteristics for DDEA permeation with adequate % CDP and sufficient solubility.
Release profiles were found to be dependent on proportion of polymer and type of permeation enhancer. The
anti-inflammatory study revealed the sustaining effect and high percentage inhibition of edema of C4/OLA
(99.68%). The acute skin irritancy studies advocated the non-irritant nature of the adhesives used.
Conclusion: It was concluded that an ideal of combination of adhesives would serve as the best choice, for
fabrication of DDEA patches, for sustained effect of DDEA with better enhancement in permeation characteristics
and robustness.
Keywords: Transdermal drug delivery system, Silicone adhesive, Acrylic adhesive, Permeation study, Dissolution,
Skin irritancy and anti-inflammatoryIntroduction
Drugs can be delivered across the skin to have an effect on
the tissues adjacent to the site of application (topical deliv-
ery) or to have an effect after distribution through the cir-
culatory system (systemic delivery). While there are many
advantages for delivering drugs through the skin the bar-
rier properties of the skin provide a significant challenge.
By understanding the mechanisms by which compounds
cross the skin it will be possible to devise means for im-
proving drug delivery [1]. In the last decades, transdermal* Correspondence: soujanya.pampana@gmail.com
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distribution, and reproduction in any mediumdosage forms have been introduced for providing a con-
trolled delivery via the skin into the circulation system.
A transdermal patch or skin patch is a medicated ad-
hesive patch that is placed on the skin to deliver a spe-
cific dose of medication through the skin and into the
blood stream. Drug-in-adhesive-type patches have been
gaining increasing popularity as effective transdermal de-
livery systems during the last two decades [2] due to
various advantages over other systems namely, they are
easy to construct, less chances of dose dumping and
patches with less thicknesses can be prepared.
Diclofenac is a well-established non-steroidal anti-
inflammatory agent, widely used in musculoskeletaltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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symptomatic relief of pain and inflammation [3]. Diethy-
lammonium salt of Diclofenac (Diclofenac Diethylamine)
is reportedly used for topical applications. Diclofenac
Diethylamine (DDEA) gel (1.16%; VoltarenW EmulgelW,
Novartis, Nyon, Switzerland) has been used extensively in
Europe since 1985 to relieve the symptoms of OA of the
knee, as well as other painful, inflammatory tendon,
ligament, muscle, and joint conditions [4]. However, all
NSAIDs include a boxed warning highlighting the poten-
tial for increased risk of cardiovascular events as well as
serious potential life-threatening gastrointestinal bleed-
ing. The drug undergoes substantial hepatic first-pass
metabolism and thus only about 50% of the adminis-
tered dose reaches systemic circulation [3,5]. This origi-
nates the need of an alternative route of administration,
which can bypass the hepatic first-pass metabolism.
Transdermal route is an alternative choice of route of
administration for such drugs. The drug, Diclofenac
Diethylamine also possesses the ideal characteristics, such
as poor bioavailability (40 to 60%), short biological half-
life (2 to 3 h), smaller dose (25 to 50 mg), etc., to be for-
mulated into a transdermal patch. Transdermal patches
offer added advantages, such as maintenance of constant
and prolonged drug level, reduced frequency of dosing,
minimization of inter and intra patient variability, self-
administration and easy termination of medication, lead-
ing to patient compliance [6].
It has been postulated that Diclofenac transdermal
exerts its pharmacological effects through localized ac-
cumulation at the site of application rather than from
the systemic absorption. The bioavailability of Diclofenac
transdermal is approximately 1% that of oral Diclofenac,
with an elimination half-life of 12 h compared with 1.2
to 2 h with oral Diclofenac [7].
The present study aimed at developing TDDS drug-in-
adhesive patches of DDEA using Silicone adhesives,
Acrylic adhesives and blend of Silicone and Acrylic
adhesives.Table 1 Details of silicone and acrylic polymers used in the st
Code Functional group Solven
Silicone Polymer
S1 Amine compatible Ethyl acet
S2 Amine compatible Ethyl acet
S3 Amine compatible Ethyl acet
S4 - Ethyl acet
S5 - Ethyl acet
S6 - Ethyl acet
Acrylic polymer
A, Polyacrylate COOH Ethylacetae andMaterial and methods
Materials
The Silicone polymers (S1 to S6) were purchased from
Dow Corning Corporation, (midland, MIA, USA), Acrylic
polymer (A) was purchased from National Starch and
Chemical company (Bridge Water, NJ, USA). Fluoropoly-
mer coated polyester release liner and Polyester Backing
laminate was purchased from 3 M Scotchpak (st. paul,
USA). The drug Diclofenac Diethylamine B.P (DDEA) was
obtained from Sparsha Pharma International Pvt Ltd
(Hyd, India). Methanol and Acetonnitrile were of HPLC
grade and purchased from Sigma-Aldrich corporation,
India. All other reagents used were of highest reagent
grade available.
Preparation of patches containing silicone adhesives
Preparation of placebo silicone patches
Transdermal patches were prepared by modified solvent
evaporation method. It is similar to conventional
method except, that the drug-polymeric solution was
spread over the release liner with the help of manual
coater over release liner. Transdermal patches using dif-
ferent silicone polymers (Table 1) without drug were
prepared. For preparing transdermal patches, an ad-
equate amount of polymeric solution was taken and then
spread over the release liner with the help of a manual
coater. The polymeric solution coated liner was dried at
80°C in an oven for 10 min. The patches were then fi-
nally laminated with polyester backing membrane. The
obtained sheets were punched using suitable dyes (3, 10
and 50 cm2) to get patches of appropriate sizes, packed
in aluminum foil and stored in a desiccator for further
studies. Patches were prepared using different grades of
silicone adhesives.
Physical evaluation of placebo patches
The tack of the patches – ball tack test
Tack is the ability of a pressure-sensitive adhesive to
bond under conditions of light contact pressure and audy
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was measured by the rolling ball tack test using primary
adhesive tester (Labthink Instruments Co. Ltd., China).
The patch with a size of 50 cm2 was fixed on a plate.
Different diameter steel balls were released from the top
of the inclined plate (angle 45°C). The number of the
largest ball (0 – 9) which did not roll down was reported
as the tack value [8].
Peel strength of patches
Peel strength measures the force required to peel away a
pressure-sensitive adhesive once it has been attached to
a surface. The test was performed with a Digital Peel
tester with a load capacity up to 5 kg (Make: Inter-
national Equipments, Model: CO). A piece of the patch
which has a width of 10 mm and length of 25 mm was
prepared, applied quickly to the end of the stainless steel
plate and left the apparatus for 10 min.
The cello tape was affixed on the product. The free end
of this tape was bending back 180° and it was attached
firmly to the upper part of a peel testing machine with a
clamp. The instrument was started with a speed of
300 mm/min and the values were recorded. Five patches
form each batch were used measuring strength and their
values were averaged [8].
Preparation of drug loaded silicone patches
Solubility of drug in adhesives
The solubility of drug in adhesive was tested in silicone
adhesives (S3 and S6). Different concentrations of drug
(5% w/w, 3% w/w, 2% w/w and 1% w/w of final patch
formulation) were added to the adhesives under constant
stirring with the help of magnetic stirrer. The stirring
was continued for a period of 4 h in order to ensure
complete mixing. The solution was kept aside overnight
for visual observation. The solutions that showed turbid-
ity were discarded and solutions that remained clear
were coated over release liner and finally laminated with
backing layer as described in the section 2.2.1.
Solubility enhancement techniques
Various solubility enhancements used to increase the
solubility of Diclofenac Diethylamine in silicone adhe-
sives include
Addition of solubilizers
Polyethylene glycol – 400 (PEG 400) and Propylene
glycol (PG) in different concentrations (% w/w of final
patch formulation) were used [9]. The adhesive
polymeric solution, drug and solubilizer in required
quantities were weighed and mixed with the aid of
magnetic stirrer for a period of about 4–5 h. The
solutions were monitored visually for appearance of
turbidity/sedimentation. The formulations that showedclear solution after 24 h were coated over release liner
and laminated with polyester backing laminate. The
patches were packed in aluminum foil, kept aside for
10 days for appearence of crystals visually and
microscopically. The patches which did not show
crystals after 10 days were selected for further study.
Addition of oils
Four oils were slected based on preliminary study to
improve the solubility of Diclofenac Diethylamine [10].
The oils, Oleic acid (OLA), Iso stearic acid (ISA),
Pharamasolve (PS) and Iso propyl myristate (IPM) in
different ratios of drug: solubilizer were mixed with
polymeric solution and then monitored visually for
turbidity. The clear solutions were used for preparation
of patches which were kept aside for 10 days for
appearance of crystals.
Ex vivo skin permeation studies
Preparation of skin barrier
Fresh full-thickness (75–80 mm) pig ear skin was used
for the study. The experiment was carried out according
to the guidelines of the Committee for the Purpose of
Control and Supervision of Experiments on Animals
and approved by Animal Ethical Committee of Depart-
ment of Genetics, Osmania University, Hyderabad,
India (approval no.380/01/a/CPCSEA). Fresh pig ears
were obtained from a local abattoir; to ensure integrity
of the skin barrier, ears were removed post-sacrifice.
The skin was dermatomed (Zimmer electric Derma-
tome Handset) to remove dermis [11,12]. The isolated
epidermis (100 μm) was rapidly rinsed with hexane to
remove surface lipids and then rinsed with water and
used immediately.
The ex vivo skin permeation from the prepared drug
polymeric patches across the porcine ear skin barrier
was studied using Franz diffusion cell (Orchid Scientifics
& Innovative India Pvt Ltd.), [13,14]. Twenty - five milli-
liters of phosphate buffer of pH 7.4 was used as an elu-
tion medium. The diameter of the donor compartment
cell provided an effective constant area of 3.4 cm2. The
dermatomed pig ear skin was mounted between the two
compartments of Franz diffusion cell with stratum cor-
neum facing towards the donor compartment. A 3 cm2
patch was used for the study. The release liner was
removed. The patches to be studied were placed in be-
tween the donor and the receptor compartment in such
a way that the drug releasing surface faced toward the
receptor compartment. After securely clamping the donor
and receptor compartments together, the elution medium
was magnetically stirred for uniform drug distribution at a
speed of 60 rpm. The temperature of the whole assembly
was maintained at 32 ± 0.5°C by thermostatic arrange-
ments. An aliquot of 0.5 mL was withdrawn at preset time
intervals for a period of 24 h and an equivalent volume of
Table 2 Draize evaluation of dermal reaction
Scoring Reaction
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lysed by HPLC described below.Erythema Edema
0 No erythema No edema
1 Very slight erythema Very slight edema
2 Well-defined erythema Slight edema
3 Moderate to severe erythema Moderate edema
4 Severe erythema Severe edemaPreparation of patches containing acrylic adhesive
The formulations containing different concentrations of
drug with acrylic adhesive were prepared by the method
described under section 2.2. The patches prepared were
monitered for appearance of crystals visually for 10 days.
The properties of acrylic adhesive were mentioned in
the Table 1. The patches which showed stability were
subjected to peel test, ball test (described under 2.2) and
permeation study (described in section 2.3).Preparation of patches containing combination of silicone
and arylic adhesives
Placebo patches containing combination of silicone and
acrylate adhesives in different ratios and drug containing
combinational patches were prepared by the following
method:
In First step, required amount of drug (% w/w of final
patch formulation) was made to dissolve completely in
appropriate amount of acrylate adhesive by continuous
stirring. Second step involves addition of silicone poly-
meric solution to clear solution formed in step 1 and
then continuing mixing for a period of 12 h. The formu-
lations that showed drug solubility after 24 h were lami-
nated into patches. The patches which showed stability
were subjected to peel test, ball test (described under
2.2) and permeation study (described in section 2.3).Effect of permeation enhancers on drug loaded
combinational patches
The incorporation of a permeation enhancer is indis-
pensable for achieving the desired permeation rate for
almost all drugs with the limited size of the patch. The
permeation enhancers Oleic acid (OLA), Iso Stearic acid
(ISA) and Isopropyl Myristate (IPM) at concentraions of
5% each were chosen to study their effect on permeation
of Diclofenac Diethylamine across the skin. The solubilized
combinational patches (C4 and C5) along with different
permeation enhancers (5% concentration) were formulated
and subjected for permeation study as described under 2.3.Table 3 Adhesive mass values, ball test and peel testCharacterization of optimized patches
Various physicochemical tests employed for optimized




S2 S3 S4 S5 S6
Ball tack test a 4 8 0 5 8
Peel test (Kg/cm) b 0.384 0.646 0.0938 0.495 0.645
(S2, S3, S4, S5 and S6 represents different Silicone polymers used; a = 3 and b = 5).Thickness
Patch thickness was measured using digital micrometer
screw gauge (Mitutoyo, Japan) at five different places.
The average and standard deviation of five readings were
calculated for each batch of the drug-loaded films.Weight uniformity
Five different films from individual batches were weighed
individuall, and the average weight was calculated the in-
dividual weight should not deviate significantly from the
weight was calculated, the individual weight should not
deviate significantly from the average weight, so the stand-
ard deviation was calculated [15].
Drug content
Assay of Diclofenac Diethylamine was done with the
help of HPLC. All the solvents used were of HPLC grade
[16].
Sample solution
For determination of drug content one patch of 50 cm2
was taken, dissolved in HPLC grade methanol and
sonicated for 15 min. From above solution 1 mL was
taken into a 50 mL volumetric flask, diluted up to the
mark with methanol, filtered through Nylon membrane
filters of 0.45 μ size (Pall Pharmalab Filtration Pvt. Ltd.)
and injected (20 mL) into the HPLC column.
Standard solution
For preparing standard solution, 50 mg of Diclofenac
Diethylamine was dissolved in 50 mL methanol (HPLC
grade). From the above solution, 1 mL was taken and
diluted to 50 mL with methanol which was finally
filtered through a Nylon membrane filters of 0.45 μ size
(Whatman GF/C) and injected (20 mL) into the HPLC
column.
HPLC conditions
The HPLC system consisted of L-7110 pump
(Shimadzu Corporation, Japan) with L-7420 variable-
wavelength ultraviolet absorbance detector (Shimadzu
Corporation, Japan) set at 274 nm. Analysis was
performed on a reversed-phase column made of silica









DS3 5% - Clear solution was
not formed.
DS3 3% - Clear solution was
not formed.
DS3 2% - Clear solution was
not formed.
DS3 1% - Clear solution indicating
solubilization of drug
DS3 0.5% - Clear solution indicating
solubilization of drug.
DS6 1% - Clear solution was
not formed.
DS3E1 5% 5% PEG-400 Clear solution was
not formed.
DS3E2 3% 5% PEG-400 Clear solution was
not formed.
DS3E3 2% 3% PEG-400 Clear solution was
formed.
DS6E4 1% 3% PEG-400 Clear solution was
formed.
DS6E5 2% 3% PEG-400 Clear solution was
not formed.
DS3G1 5% 5% PG Clear solution was
not formed.
DS3G2 2% 5% PG Clear solution was
formed.
DS3G3 1% 2% PG Clear solution was
formed.
DS3O1 3% 2% OLA Clear solution was
not formed
DS3O2 2% 2% OLA Clear solution was
not formed
DS3O3 1% 2% OLA Clear solution was
formed
DS3I1 4% 2% ISA Clear solution was
not formed
DS3I2 3% 2% ISA Clear solution was
not formed
DS3I3 1% 2% ISA Clear solution was
formed










DS: drug with silicone polymer; S3: Silicone polymer grade, S3; S6: Silicone
polymer grade S6; OLA: oleic acid; ISA: Iso stearic acid; IPM: Isopalmitic acid;
PEG 400: Polyethylene glycol −400; PG: Propylene glycol.
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Beijing China), operated at 40°C. The mobile phase
consisted of 45: 55 ratio of 0.5% Glacial acetic acid in
water and Acetonitrile. HPLC grade water was used for
the preparation of 0.5% Glacial acetic acid solution.
The flow rate of mobile phase was set at 0.8 mL/min,
was used. The injection volume is 20 μL.
In vitro release – dissolution studies
The release-rate determination is one of the most im-
portant studies to be conducted for all controlled release
delivery systems. The dissolution studies of patches are
very crucial, because one needs to maintain the drug
concentration on the surface of stratum corneum con-
sistently and substantially greater than the drug concen-
tration in the body, to achieve a constant rate of drug
permeation [17].
A Paddle over disc assembly (USP 23, Apparatus 5)
was used for the assessment of release of DDEA. The
TDDS patch was mounted on the disc and placed at the
bottom of the dissolution vessel. The dissolution medium,
900 ml degassed distilled water at pH 7.0. The apparatus
was equilibrated to 32 ± 0.5°C and operated at 50 rpm
[18] during the entire study period (24 h). The dissolution
medium was degassed by a combination of heating up to
45°C and vacuum filtration followed by vigorous stirring
of media under vacuum.
Stability study
The optimized formulations were subjected to stability
study by storing patches at 40 ± 2°C and 75% RH in sta-
bility chamber for three months. Two parameters
namely, peel strength and drug content were analyzed.
Surface morphology
The surface morphology of formulated transdermal
patches (both stable and unstable) were investigated by
using Scanning electron microscope (model: SEM JSM-
6610) at 15 kV under different magnifications (950x,
1000x and 1500x). In order to make the samples elec-
trically conductive the samples were gold coated prior to
the study.
Acute skin irritancy test
The study was conducted on the basis of the approval of
institutional animal ethical committee. Albino rabbits of
either sex, each weighing 1.5 to 2.0 kg, divided into two
groups, were used in this study (n = 4 in each group)
[14]. They were housed in cages in the animal house
under controlled temperature and light conditions. They
were fed a standard laboratory diet and had access to
water ad libitum. The dorsal surface of the rabbits was
cleared and the hair was removed by shaving. The skin
was cleared with rectified spirit. The experimental patch
Figure 1 Photograph of Silicone patch, DS3O1, showing crystal
formation.
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shaved skin of rabbits and secured using USP adhesive
tape (Johnson & Johnson limited, Mumbai). A 0.8% (v/v)
aqueous solution of formaldehyde was applied as a
standard irritant (group I). Its effect was compared with
the test [19]. The animals were observed for any sign ofFigure 2 Photograph of Silicone patch, DS3I3, showing crystal
formation.erythema and edema for a period of 7 days and scored
as reported by Draize et al. (1944) [20]. The Draize
method of scoring was shown in Table 2.
Anti-inflammatory study
The study was conducted in accordance with the Ethical
Guide- lines for Investigations in Laboratory Animals
and was approved by the Ethics Review Committee for
Animal Experimentation of Osmania University. The anti-
inflammatory activity and sustaining action of the drug-
loaded drug in adhesive patches were evaluated using
“carrageenan-induced hind paw edema” method devel-
oped by Winter et al. (1965) [21]. Wistar rats were used
after being allowed to acclimatize for 1 week. Before the
day of administration, rats were fasted overnight but were
allowed access to water ad libitum. Eight rats weighing
180–220 g (6–8 weeks old) divided into two groups were
used for the study. The backsides of rats were shaved 12 h
before starting the experiments.
Group – I (Control group): Paw edema was induced
by injecting 0.1 mL of a 1% w/v homogeneous suspen-
sion of carrageenan in double-distilled water [21] The
volume of injected paw was measured immediately (0 h)
and at 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 h
after injection using a IMCORP plethysmometer [22].
The amount of paw swelling with respect to initial vol-
ume was determined time to time. It is obtained by sub-
tracting volume of injected paw at time ‘0’ from volume
of injected paw at time ‘t’ divided by volume of injected
paw at time ‘0’.
Group – II (Test): Treated similar to control group ex-
cept that patches were applied half an hour before sub-
plantar injection of carrageenan. Percent (%) inhibition
of edema produced by each patch- treated group was
calculated against the respective control group using the
following formula
% Inhibition ¼ % edema controlð Þ–% edema drugð Þ
=% edema controlð Þ  100
ð1Þ
Results and discussion
Evaluation of placebo silicone patches
The placebo patches using six grades of silicone polymer
were prepared. The patches were smooth, flexible and
uniform. The S1 patches were ruled out because during
preparation of patches after drying the polymer com-
pletely lost its adhesive property.
An ideal adhesive polymer for drug-in-adhesive system
is one that exhibit greater adhesion value. The initial
screening of the silicone adhesives was done by ball tack
test and peel strength of patches. The peel test, ball test
and adhesive mass test values of all placebo silicone











DS3 0.5% - No sign of crystallization Same as first day
DS3 1% - No sign of crystallization Same as first day
DS3E3 2% 3% PEG-400 No sign of crystallization Oil globules were formed and the solution turned oily
DS6E4 1% 3% PEG-400 No sign of crystallization Oil globules were formed and the solution turned oily
DS3G2 2% 5% PG No sign of crystallization. Oil globules were formed and the solution turned oily
DS3G3 1% 2% PG No sign of crystallization. Oil globules were formed and the solution turned oily
DS3O3 1% 2% OLA Crystallization was seen. Same as first day
DS3I3 1% 2% ISA Crystallization was seen. Same as first day
DS3O4I4 3% 5% OLA & 5% ISA Crystallization was seen. Same as first day
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The ball test and peel test values for different formula-
tions of thickness 200 μm were in the following order:
S3 > S6 > S5 > S2 > S4. Hence, S6 and S3 polymers
showed better peel adhesion and ball test values hence,
selected for further study.
Evaluation of drug loaded silicone patches
Solubility of drug in pure silicone adhesives
The solubility of Diclofenac Diethylamine in S3 and S6
was tested. The solutions that remained clear after 24 h
were coated over the release liner. Results were shown
in (Table 4). The Polymeric adhesive S3 only showed
clear solution with 1% drug concentration. The results
indicated low solubility of Diclofenac Diethylamine in
Silicone adhesives and stresses on the need for the solu-
bilizers for solubilization of drug.
Solubility enhancement techniques
Solubility of Drug in Silicone adhesives in the presence of
solubilizers
Two solubilizers namely PEG - 400 and PG were tested






CDP (μg/cm2) % CDP CDP (μg/cm2) % CDP
1. 0 0 0 0 0
2. 2 1.185 1.405138 5.934 0.84051
3. 4 2.6843 3.182964 12.847 1.819688
4. 6 4.2813 5.07664 19.131 2.709773
5. 8 5.9842 7.095889 25.819 3.657082
6. 10 7.7583 9.199565 31.824 4.507649
7. 12 9.3142 11.04451 38.119 5.399292
8. 14 11.042 13.09328 45.248 6.409065
9. 24 19.573 23.20909 75.692 10.72125
CDP: Cumulative drug permeated; % CDP: percent cumulative drug permeated;
DA: drug with Acrylic polymer alone.Silicone adhesives. Though PEG - 400 and PG increased
Diclofenac Diethylamine solubility in water [9], their role
to solubilize the drug in Silicone adhesive was abortive.
Table 4 shows the drug concentration and solubilizer
concentration used. Except few, all the solutions showed
turbidity. In case of DS3E3 a clear solution was formed
with 2% drug and 3% PEG - 400 while, in formulations
containing S6 polymer (DS6E5) a clear solution was not
formed with 2% drug and 3% PEG - 400. Similar to PEG -
400, PG showed slight improvement in solubility of drug
in S3 polymer.
From solubility studies, it can be concluded that com-
pared to S6, S3 polymer showed solubilization of DDEA
to some extent. So, S3 polymer was chosen for further
study.
Solubility of Drug in Silicone adhesives in the presence of oils
As formulations with PEG - 400 and PG showed little/no
improvement in solubility, various oils namely oleic acid
(OLA), IsoStearic acid (ISA), PharmsolveW and Isopropyl
Myristate (IPM) were tested for their ability to improve
solubility of drug using the method described in experi-
mental section. The formulations which remained clear
after 24 h were coated over release liner. Among various
oils tested, OLA and ISA were promising. However, onlyTable 7 Solubilization summary, peel test, ball test and
adhesive mass value for acrylic adhesive patches
Polymer Drug concentration Observation
A 10% Clear solution formed
A 15% Clear solution formed
A 20% Clear solution formed
A 25% Clear solution was not formed
Parameter evaluated DA
Peel test (Kg/cm) 0.9306
Ball test 8
(n is equal to 5 and 3 for Peel test and Ball test respectively).









C1 10: 90 10% YES
C2 20: 80 10% YES
C3 30: 70 10% YES
C4 40: 60 10% YES
C5 50: 50 10% YES
C6 60: 40 10% NO
C7 70: 30 10% NO
C8 80: 20 10% NO
C9 90: 10 10% NO
C: combination patches with Acrylic and Silicone adhesives.
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DS3I3) While, IPM and Pharmsolve
W did not even
solubilize 1% drug. Combination of solubilizers was also
tested but, only 3% drug solubilization was achieved in S3
polymeric adhesive at 10% solubilizer concentration (OLA
and ISA, 5% each).
The prepared patches (DS3 with 1% drug, DS3E3,
DS6E4, DS3G2, DS3G3, DS3O3, DS3I3 and DS3O4I4)
were uniform. However, after 10 days patches with
additives OLA and ISA (DS3O3, DS3I3 and DS3O4I4)
ended up with formation of crystal growth. Figure 1
and Figure 2 shows crystallization in patches DS3O3
and DS3I3, respectively.
In case of formulations containing PEG - 400 and PG as
additives, though the patches showed no crystallization,
the solutions after 10 days took oil like consistency due to
formation of oil globules in the solution resulting in loss
of adhesion (Table 5).
The patches which did not contain any additives
remained clear even after 10 days hence considered
stable. Among various formulations prepared, DS3 con-
taining 1% drug was chosen for further study.Figure 3 Graph showing cumulative amount of drug permeated (CDP
combinational patches (C4/OLA, C4/ISA and C4/IPM reprsents C4 patch
permeation enhancers, respectively. Similar in case of C5 combinationalEx vivo skin permeation study
The DS3 patch containing 1% drug was chosen for con-
ducting permeation study. The cumulative amount of
drug permeated (CPD) at the end of 24 h was found to be
19.573 mcg/cm2 (Table 6). Though the amount of drug
permeated was low, the percentage cumulative amount of
drug permeated was 23.209%. The low CPD value might
be due to less amount of drug (1%) in the patch.
Evaluation of drug loaded acrylic patches
The extensive solubilization study conducted revealed
that the silicone polymer is unsuitable for achieving very
high concentrations of DDEA. Hence, solubility of drug
in acrylic adhesive was tested by method described
under experimental section I of IIIA. It was noticed that
drug concentrations up to 20% was solubilized without
use of any additives. The prepared patches were also
stable after 10 days and did not showed crystal forma-
tion. While 25% of drug polymeric solution resulted in
turbidity (Table 7). This might be because of drug load-
ing greater than the saturation solubility of the drug in
the adhesive used. However, the concentration of drug
was fixed at 10% for further study since the formulation
being studied is intended for topical use. The Ball test
and peel strength values for DA were shown in Table 7.
Ex vivo skin permeation study
Skin permeation of Diclofenac Diethylamine was studied
using DA patch containing 10% drug. Study was con-
ducted for 24 h without using permeation enhancer. The
cumulative amount of drug permeated into the receptor
compartment was 75.692 mcg/cm2 after 24 h (Table 6)
that represents 10.72% of the total drug placed in the
donor compartment.
Though the CDP of DA was significantly greater than
CDP of DS3 the percent drug permeated was high in
case of DS3 (23.209%). The CDP of DA was found to be) at the end of 24 h with and without permeation enhancers for
with oleic acid (OLA), Isostearic acid and Isopalmitic Myristate as
patches).
Figure 4 Graph showing the plot between Flux (μg/cm2.h) and time (h) for C1, C2, C3, C4 and C5 patches (data represented as mean ± S.D).
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was 10 times greater than that of DS3.Evaluation of drug loaded combinational patches
Studies on Silicone adhesives revealed poor solubilization
capacity and high percent cumulative drug permeation
(%CDP) value whereas; acrylic polymers solubilized higher
concentrations of drug but exhibited less%CDP. Hence an
attempt was made to combine high%CDP property of Sili-
cone and greater drug solubilization property of acrylic
polymer by fabricating a drug formulation with combin-
ation of adhesives.
The placebo solutions containing different proportions
of Silicone and Acrylic adhesives were prepared and
used as reference for checking the solubility of drug in
combination of adhesives. The combinations from C1 to
C5 showed similar consistency as compared to respectiveFigure 5 Graph showing the plot between cumulative amount of dru
and C4/OLA (data represented as mean ± S.D).placebo patches after addition of drug. Table 8 shows
the Solubility data of different combinations of Silicone
and acrylic with 10% drug. The results indicated that
minimum 50% acrylic polymer is required in the formu-
lation to achieve 10% drug solubility (As acrylic polymer
alone can solubilize 20% drug without any solubilizer as
mentioned earlier, it is evident that 50% acrylic polymer
is sufficient to solubilize 10% drug). Hence, formulations
C1, C2, C3, C4 and C5 were used for further study.Ex vivo skin permeation experiment
In all the combinational patches, the CDP of combin-
ational patches was higher than that DA patches which
contains Acrylic polymer alone. Figure 3 shows the
amount of drug permeated at the end of 24 h with and
without combinational patches. The CDP of different
combinational patches were in the following order:g permeated (CDP, μg/cm2) and time (h) for DA, C4, C5, C5/OLA
Figure 6 Graph showing the Higuchi plot for DS3, DA, C5/OLA and C4/OLA (data represented as mean ± S.D).
Figure 7 SEM micrographs of optimized formulations before and after stability study: (a) and (c) represent C4/OLA and C5/OLA patches
before stability, respectively; (b) and (d) represent C4/OLA and C5/OLA patches after stability, respectively.
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Table 9 Stability data for formulation C4/OLA and C5/OLA
Tested parameters 0 days 45 days 90 days
C4/OLA
Peel Strength (Kg/cm) 0.663 0.646 0.659
Drug content (%) 104.6 103.6 104.1
C5/OLA
Peel Strength (Kg/cm) 0.654 0.649 0.652
Drug content (%) 101.64 98.86 94.38
(C4/OLA: C4 combination patch with oleic acid, OLA, as permeation enhancer;
C5/OLA: C5combination patch with oleic acid, OLA, as permeation enhancer;
n=3 for Drug content and n=5 for Peel strength). Figure 9 Photograph of the patches C5/OLA after stability.
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The above order once again reflected the previous
results i.e. with increase in amount of Silicone polymer
the amount of CDP increased. Among all five formula-
tions C5 displayed high CDP value due to its high Sili-
cone content (50% of the total polymer).
Figure 4 shows plot between flux and time for all the
five combinations. The graph showed little/less variation
in the flux between different time intervals for C4 and
C5. Moreover, the CDP was found to be relatively high
for these two formulations. Hence, the formulations C4
and C5 were chosen for further study.
Effect of permeation enhancers on the permeation of
DDEA
Three permeation enhancers namely, OLA, ISA and
IPM were used at 5% concentration. The cumulative
amount of drug permeated at the end of 24 h was repre-
sented in Figure 3. The permeation data revealed greater
penetration enhancing capability of OLA than ISA and
IPM. This is in line with the result reported where OLA
increased the permeation of DDEA by 7–9 folds (Hus-
sain Shah et al. 2012) [10]. Thus, it can be concluded
that vehicles used here were predominantly influencing
the partition of the drug into the skin. Hence, C4/OLA
and C5/OLA which exhibited greater CDP among all
were chosen as optimized formulations.
Figure 5 shows the plot between CDP and time for dif-
ferent formulations. From the graph, it can be predictedFigure 8 Photograph of the patches C4/OLA after stability.that C4 and C5 showed high CDP compared to DA indi-
cating more drug permeation capacity compared to
individual Acrylic formulations. OLA application as a
permeation enhancer was well justified as significant in-
crease in CDP value was observed compared to patches
without enhancers.
Dissolution study of patches
In vitro release profile is an important tool that predicts
in advance how the drug will behave in vivo. Thus, we
can eliminate the risk of hazards during experimentation
in living system. Five patches, DS3, DA, C4/OLA and
C5/OLA were studied for drug release. The study was
conducted for a period of 24 h. The percent drug release
(Figure 6) was found to be in the following order:
C5=OLA > C4=OLA > DS3 > DA
The dissolution values revealed that formulations con-
taining OLA exhibited greater percent cumulative drug
release (%CDR) than DS3 and DA. This might be due to
increased solubility of poorly soluble drug, DDEA, in
water due to OLA. Among C5/OLA and C4/OLA the
formulation containing greater portion of silicone poly-
mer, C5/OLA, showed greater%CDR.
Release kinetics
The dissolution data of C4/OLA and C5/OLA was put
forth for release kinetic studies. Based on high R2 value
it was shown that drug release from the formulations
followed Higuchi pattern of drug release, with R2 value
0.978 for C4/OLA and 0.981 for C5/OLA, (Figure 6)
where drug diffusion through the polymeric system was
the main mechanism. The ‘n’ value from the
korsemeyer-peppas plot revealed non-fickian/anomalous
diffusion pattern (n>0.5).
Stability study
The formulations C5/OLA and C4/OLA were kept for
3 month stability study. During stability study in case of
Figure 10 Photograph of optimized C4/OLA patches both 10 cm
2 (a) and 3 cm2 (b) patches.
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might be due to saturation of drug solubility which
resulted in slow precipitation of drug. This is also
reflected in its drug content shown in Table 9 where the
percent drug content of the formulation kept on de-
creasing. Such a saturated matrix is unstable and the
drug will recrystallize in such systems over time [23-25].
Recrystallization may however not be apparent immedi-
ately after manufacture because of the relatively low
diffusion coefficients of drug in such highly viscous sys-
tems and the requirement of nucleation for the initiation
of crystallization. Figure 8 shows the photograph of the
C4/OLA after stability with no crystals and Figure 9
shows photograph of the C5/OLA after stability with
crystal formation.
The peel test of both the formulations showed no signifi-
cant change during stability study indicating the sustain-
ability of adhesive property of the polymeric combination.
However, in case of C4/OLA crystallization was not
found and moreover the drug content remained stable
representing robustness of the formulation during 3 month
stability. Hence, the formulation C4/OLA was found to be
the optimized formulation.Table 10 Acute skin irritancy data for C5/OLA (n = 4)
Day Parameter Standard Test
1 2 3 4 1 2 3 4
Day 0 Erythema 0 0 0 0 0 0 0 0
Edema 0 0 0 0 0 0 0 0
Day 7 Erythema 4 4 3 4 0 1 1 1
Edema 3 2 2 3 0 0 0 0
(C4/OLA: C4combination patch with oleic acid, OLA, as permeation enhancer).Physical evaluation of optimized patches
Figure 10(a) and 10(b) shows the original patch C4/OLA
of sizes 10 cm2 and 3 cm2, respectively. The optimized
formulation C4/OLA was tested for various physical para-
meters. The thickness (n = 5) of C4/OLA patches was
found to be 181.63 ± 0.03 μm. Good weight uniformity
among the batches was observed for all formulations and
ranged from 214.33 – 216.35 mg. The results indicate that
the process which was employed to prepare patches in this
study was capable to produce patches with uniform drug
content and minimal patch variability.Acute skin irritancy study
The 7 day skin irritancy study revealed that the test for-
mulation showed a skin irritation score (erythema and
edema) of less than 1 (Table 10 & Figure 11). From the
Draize method of scoring, the control animals showed
severe erythema and moderate to slight edema whereas
the test animals showed only very slight erythema and
no edema on the site of application. According to Draize
et al. (1944) [20] compounds producing scores of 2 or
less are considered non-irritant [14]. Hence from the
study, we can conclude that formulations are non-irritable
to skin and safer for therapeutic use.In vivo anti-inflammatory studies
The result of carrageenan induced paw edema test was
shown in the Table 11. The table shows the data for the
percent increase in edema with respect to initial volume
and percentage inhibition of edema with respect to con-
trol during 24 h study for the test formulation. As shown
in the table in case of control group animals, the mean
percent increase in edema with respect to initial volume
(Group –I) was 114.3 ± 15.0 at the end of 24 h which is
because of swelling nature of carrageenan. While in case
of test group animals the value is 0.37 ± 0.54 at the end
of 24 h indicating that test patches, C4/OLA, are
Figure 11 Images of skin irritancy study: (a) patch application to shaved area; (b) skin of rabbit at 0 day; (c) skin of test group rabbit
after 7 days of patch application; (d) skin of standard group rabbit after 7 days.
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tion. Moreover, the test group animals showed 99.68%
inhibition of edema with respect to control after 24 h
indicating the efficacy of the formulation during the
period. The initial percent increase in edema with re-
spect to initial volume in case of test group half an hour
after the carrageenan induction was 0.4 ± 0.54 as
opposed to Control group (3.57 ±1.08) indicating that
the test patch, C4/OLA showed action from the first
hour without any appreciable lag time. Throughout the
study the percent increase in edema value with respect
to initial volume for test group remained well below
than the control group indicating the sustaining effect of
the drug against carrageenan challenge.Table 11 Paw edema data obtained on carrageenan induced
represented as mean ± S.D, n = 4)
Time
0.5 0.75 1 2 3 4 5
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88.80 60.78 68.36 56.78 21.20 10.87 12.45
(C4/OLA: C4combination patch with oleic acid, OLA, as permeation enhancer).Conclusion
The extensive solubilization study conducted on Silicone
adhesive polymers revealed their unsuitability in fabrica-
tion of DDEA transdermal patches alone as not more
than 1% drug was solubilized even with high concentra-
tion of solubilizer. On the other hand, Acrylic polymer
showed high drug loading and greater control releasing
capacity hence, alone can be used for fabricating trans-
dermal patches of DDEA. However, use of Acrylic alone
requires greater amount of drug incorporation due to its
low value of percent cumulative drug permitted (10.72%).
Hence, the combinations of adhesives were tested with
the objective combining the greater permeation capacity
of Silicone polymer and greater drug loading capacity ofrats half an hour after the patch application (data
(h)
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ith respect to control
36.51 54.09 63.80 80.92 87.15 97.94 99.68
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the both the desired properties were successfully prepared.
Among various permeation enhancers tested OLA proved
to be a good permeation enhancer as compared to ISA
and IPM for DDEA. C4/OLA was found to be optimized
formulation displaying robustness in stability. The skin ir-
ritancy study revealed the non-irritant nature of the C4/
OLA patches and sustaining action of the patches were
confirmed by anti-inflammatory test by carrageenan
induced paw edema model. Thus, it can be concluded that
an ideal of combination of adhesives would serve as the
best choice, for fabrication of DDEA patches, for sustained
effect of DDEA with better enhancement in permeation
characteristics and robustness.
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